Atlas Trials

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

Clinical trial NCT05243329 · UNKNOWN

Trial details

NCT number
NCT05243329
Sponsor
Halucenex Life Sciences Inc.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Treatment Resistant DisordersPost Traumatic Stress Disorder
Start date
2022-10-03
Primary completion
2023-10-30
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.